MedTrace Logo

Care Coordination to Assess Improvement in Outcomes in Hospital Readmissions

NCT04905160 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2024-03-20

No results posted yet for this study

Summary

Heart failure is a syndrome that is defined by distinctive clinical, hemodynamic, and neurohormonal findings. HF represents a final common pathway for many different cardiovascular diseases, including coronary disease, hypertension, Valvular disease, and many primary heart muscle diseases. Clinically, HF patients experience dyspnea, fatigue and diminished exercise tolerance, reflecting elevated left and/or right ventricular filling pressures and decreased cardiac output.

Conditions

Interventions

OTHER

COMPASSION Digital Biomarker

Vitals data collected by the Vitalbeat workbench for biomarker based algorithm variables will be used to drive intervention based on PAP systolic and diastolic pressures.

Sponsors & Collaborators

  • TwinEpidemic

    collaborator UNKNOWN

  • Arizona State University

    collaborator OTHER

  • Intel Corporation

    collaborator INDUSTRY

  • Heart Health Organization East Valley

    collaborator UNKNOWN

  • Aventyn, Inc.

    lead INDUSTRY

Principal Investigators

  • Kris Vijay, MD · Abrazo Arizona Heart

  • Raj Bhat, MD · Pioneer Hospitalists

  • Zaki Lababidi, MD · Gilbert Cardiology

  • Ashok Solsi, MD · Premier Cardiovascular Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-02-18
Primary Completion
2025-02-22
Completion
2026-12-22

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04905160 on ClinicalTrials.gov